Challenges in Facing the Lung Cancer Epidemic and Treating Advanced Disease in Latin America

详细信息    查看全文

• 作者：Luis E. Raez¹ ; ² ; ^{lraez@mhs.net} ; Edgardo S. Santos³ ; Christian Rolfo⁴ ; Gilberto Lopes⁵ ; Carlos Barrios⁶ ; Andres Cardona⁷ ; Luis A. Mas⁸ ; Oscar Arrieta⁹ ; Eduardo Richardet¹⁰ ; Carlos Vallejos S¹¹ ; Ignacio Wistuba¹² ; David Gandara¹³ ; Fred R. Hirsch¹⁴
• 关键词：ALK ; EGFR ; Molecular markers ; Screening ; Targeted therapy
• 刊名：Clinical Lung Cancer
• 出版年：2017
• 出版时间：January 2017
• 年：2017
• 卷：18
• 期：1
• 页码：e71-e79
• 全文大小：474 K
• 卷排序：18

文摘

Lung cancer, the deadliest cancer worldwide, is of particular concern in Latin America. The rising incidence poses a myriad of challenges for the region, which struggles with limited resources to meet the health care needs of its low- and middle-income populations. In this environment, we are concerned that governments are relatively unaware of the pressing need to implement effective strategies for screening, diagnosis, and treatment of lung cancer. The region has also been slow in adopting molecularly-based therapies in the treatment of advanced disease: testing for epidermal growth factor receptor mutations and anaplastic lymphoma kinase rearrangements are not routine, and access to targeted agents such as monoclonal antibodies and tyrosine kinase inhibitors is problematic. In this paper, we review the current situation in the management of lung cancer in Latin America, hoping that this initiative will help physicians, patient associations, industry, governments, and other stakeholders better face this epidemic in the near future.